BLRX - BioLineRx Ltd.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
0.9064
-0.0036 (-0.40%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.9100
Open0.9100
Bid0.8710 x 5600
Ask0.9900 x 1000
Day's Range0.9000 - 0.9300
52 Week Range0.7800 - 1.3400
Volume72,846
Avg. Volume355,077
Market Cap97.27M
Beta0.45
PE Ratio (TTM)N/A
EPS (TTM)-0.2520
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
Trade prices are not sourced from all markets
  • CTI BioPharma Tanks Post Type B Talks on Pacritinib With FDA
    Zacks3 days ago

    CTI BioPharma Tanks Post Type B Talks on Pacritinib With FDA

    CTI BioPharma (CTIC) conducts Type B meeting with the FDA to discuss a regulatory pathway for its lead pipeline candidate Pacritinib, currently under study for the treatment of myelofibrosis.

  • Aclaris' Alopecia Candidate Gets Fast Track Designation
    Zacks12 days ago

    Aclaris' Alopecia Candidate Gets Fast Track Designation

    The FDA grants fast track status to Aclaris' (ACRS) JAK-inhibitor, ATI-502, for the treatment of alopecia areata.

  • Benzinga13 days ago

    The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials

    Biotech stocks held their ground in a holiday-shortened week amid a drought of market-moving catalysts. Looking ahead, the following are catalytic events for biotech investors to watch.  Conferences Fourth ...

  • Aclaris Stock Up on JAK Inhibitor's Encouraging Activity
    Zacks16 days ago

    Aclaris Stock Up on JAK Inhibitor's Encouraging Activity

    Aclaris Therapeutics (ACRS) posts positive interim data from a phase II study on its Alopecia Areata candidate, ATI-502.

  • BioLineRx Sees Hammer Chart Pattern: Time to Buy?
    Zacks23 days ago

    BioLineRx Sees Hammer Chart Pattern: Time to Buy?

    BioLineRx Sees Hammer Chart Pattern: Time to Buy?

  • Shire (SHPG) HAE Drug Gets FDA Nod for Pediatric Population
    Zackslast month

    Shire (SHPG) HAE Drug Gets FDA Nod for Pediatric Population

    Shire (SHPG) gains FDA approval for expanding the label of its hereditary angioedema (HAE) drug, Cinryze, to include its usage among pediatric patients aged six years and older.

  • PR Newswirelast month

    BioLineRx Presents New Overall Survival Data From Phase 2a Study for BL-8040 in r/r AML Patients

    TEL AVIV, Israel, June 18, 2018 /PRNewswire/ -- BioLineRx Ltd. (BLRX) (BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that new data presented at the 23rd Annual Congress of the European Hematology Association (EHA), held in Stockholm, Sweden, shows that BL-8040, combined with high dose cytarabine (HiDAC), significantly enhanced overall survival in difficult-to-treat relapsed or refractory AML (r/r AML) patients in a Phase 2a clinical trial.

  • PR Newswirelast month

    BioLineRx to Participate at JMP Securities 2018 Life Sciences Conference

    TEL AVIV, Israel , June 13, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that its Chief ...

  • PR Newswire2 months ago

    BioLineRx Reports First Quarter 2018 Financial Results

    TEL AVIV, Israel , May 22, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its financial results ...

  • PR Newswire2 months ago

    BioLineRx to Present Overall Survival Data at EHA from Phase 2a Study of BL-8040 in r/r AML Patients

    BioLineRx Ltd. (BLRX) (BLRX.TA), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that it will present data at the 23rd Annual Congress of the European Hematology Association (EHA), to be held June 14-17, 2018 in Stockholm, Sweden, showing that BL-8040, combined with high dose cytarabine (HiDAC), significantly enhanced overall survival of difficult-to-treat relapsed or refractory AML (r/r AML) patients in a Phase 2a clinical trial. Patients with r/r AML were treated daily with BL-8040 monotherapy for two days followed by combined administration of BL-8040 and HiDAC for 5 days for 1-2 cycles.

  • ACCESSWIRE2 months ago

    Breakfast Technical Briefing on BioLine Rx and Three More Biotech Stocks

    LONDON, UK / ACCESSWIRE / May 17, 2018/ If you want a free Stock Review on BLRX sign up now at www.wallstequities.com/registration. In today's pre-market research, WallStEquities.com evaluates Aratana Therapeutics Inc. (NASDAQ: PETX), BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), BioDelivery Sciences International Inc. (NASDAQ: BDSI), and BioLine Rx Ltd (NASDAQ: BLRX).

  • PR Newswire2 months ago

    BioLineRx Reports Results of Phase 2 Study for BL-8040 Monotherapy in Stem Cell Mobilization for Allogeneic Bone Marrow Transplantation

    TEL AVIV, Israel, May 17, 2018 /PRNewswire/ -- BioLineRx Ltd. (BLRX) (BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today positive results from a Phase 2 clinical trial assessing BL-8040 as a single agent for hematopoietic stem cell mobilization in an allogeneic transplantation setting. Mobilization of hematopoietic stem and progenitor cells (HSPCs) for the purpose of donor (allogeneic) transplantation after high-dose chemotherapy is currently performed using a 4-5 day treatment cycle with G-CSF and a 1-2 day apheresis procedure. This proof-of-concept Phase 2 study, consisting of 24 donor/recipient pairs, assesses the ability of BL-8040 monotherapy to mobilize HSPCs for transplantation in a single administration.

  • Benzinga2 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Biolinerx Ltd/S ADR (NASDAQ: BLRX ) stock was trading ...

  • PR Newswire2 months ago

    BioLineRx to Report First Quarter 2018 Results on May 22, 2018

    Management to hold a conference call at 10:00 a.m. EDT TEL AVIV, Israel , May 16, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX)( TASE: BLRX)( BLRX) , a clinical-stage biopharmaceutical company focused ...

  • PR Newswire2 months ago

    BioLineRx Announces Grant of European Patent Covering Use of BL-8040 with Cytarabine for Treating Acute Myeloid Leukemia

    BioLineRx Ltd. (BLRX)(BLRX.TA)(BLRX) , a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that the European Patent Office (EPO) has issued a Decision to Grant a patent claiming the use of BL-8040 with cytarabine, a chemotherapeutic agent, for the treatment of acute myeloid leukemia (AML). This patent will be valid through March 2034, with the option of up to five years' patent term extension. Member patents were also granted in Japan and Hong Kong. Additional corresponding patent applications are pending in China (a Notice of Acceptance was received), Israel (a Notice of Acceptance was received), the United States, India, Korea, Mexico, Brazil, Canada and Australia.

  • Moving Average Crossover Alert: BioLineRx Ltd. (BLRX)
    Zacks4 months ago

    Moving Average Crossover Alert: BioLineRx Ltd. (BLRX)

    Moving Average Crossover Alert: BioLineRx Ltd. (BLRX)

  • ACCESSWIRE4 months ago

    Wired News – vTv Therapeutics Completed Phase-1b Study Evaluating TTP399 for Treatment of Type-1 Diabetes

    Stock Monitor: BioLine Rx Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 27, 2018 / Active-Investors.com has just released a free research report on vTv Therapeutics Inc. (NASDAQ: VTVT ). If you ...

  • PR Newswire4 months ago

    BioLineRx Announces Notice of Allowance From USPTO for Patent Covering AGI-134 - a Novel Immunotherapy for Treating Solid Tumors

    TEL AVIV, Israel, March 26, 2018 /PRNewswire/ --  BioLineRx Ltd. (BLRX) (BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that a Notice of Allowance has been issued by the United States Patent and Trademark Office (USPTO) for a patent application claiming the use of AGI-134, a novel immunotherapy compound, for the treatment of solid cancer tumors. This patent, when issued, will be valid until May 2035 with a possibility of up to five years patent term extension. Additional corresponding patent applications for AGI-134 are pending in Europe, Japan, China, Canada, Australia and Israel.

  • PR Newswire4 months ago

    BioLineRx to Present at the 28th Annual Oppenheimer Healthcare Conference

    TEL AVIV, Israel , March 14, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that its Chief ...

  • ACCESSWIRE5 months ago

    Bioline RX Ltd Sponsored ADR to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 6, 2018 / Bioline RX Ltd Sponsored ADR (NASDAQ: BLRX ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 6, 2018, at 10:00 AM Eastern ...

  • PR Newswire5 months ago

    BioLineRx Reports Year End 2017 Financial Results

    TEL AVIV, Israel , March 6, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its financial results for ...

  • PR Newswire5 months ago

    BioLineRx to Report Annual 2017 Results on March 6, 2018

    Management to hold a conference call at 10:00 a.m. EST TEL AVIV, Israel, Feb. 27, 2018 /PRNewswire/ --  BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on ...

  • PR Newswire5 months ago

    BioLineRx to Present at 2018 BIO CEO & Investor Conference in New York on February 13

    TEL AVIV, Israel , Feb. 6, 2018 /PRNewswire/ --  BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that its Chief ...

  • PR Newswire6 months ago

    BioLineRx Presents Preclinical Data at ASCO-SITC Showing BL-8040 Prolongs Survival by Mediating Tumor Infiltration of Antigen-Specific T-cells

    BioLineRx Ltd. (BLRX) (BLRX) (BLRX.TA) a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today the publication of data showing that BL-8040, its lead oncology platform, augments the ability of the immune system to fight cancer by increasing the infiltration of anti-tumor-specific T-cells into the tumor microenvironment (TME), resulting in decreased tumor growth and prolonged survival in a murine model of cancer. Results of the study will be presented as a poster titled "CXCR4 Antagonist (BL-8040) Enhances Antitumor Effects by Increasing Tumor Infiltration of Antigen-specific Effector T-cells" (Abstract 73) on January 25, 2018 at the ASCO-SITC Clinical Immuno-Oncology Symposium, being held January 25-27, 2018, in San Francisco, CA. In the preclinical study, a murine model of cancer was used to assess the effects of BL-8040 in combination with a cancer vaccine that primes the immune system against the tumor.

  • PR Newswire6 months ago

    BioLineRx Reports Data at ASCO-SITC Conference Showing Complete Tumor Regression by AGI-134 in Pre-Clinical Studies

    BioLineRx Ltd. (BLRX) (BLRX) (BLRX.TA), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that AGI-134, an immunotherapy compound in development for the treatment of multiple solid tumors, demonstrated successful results in two pre-clinical melanoma studies. Results of these studies will be presented as a poster titled "Intratumoral Administration of the Alpha-Gal Glycolipid AGI-134 to Induce Tumor Regression in a Mouse Model of Melanoma" (Abstract 68) on January 25, 2018 at the ASCO-SITC Clinical Immuno-Oncology Symposium, being held January 25-27, 2018, in San Francisco, CA. The ability of intratumorally injected AGI-134 to induce regression of established primary tumors was assessed in two murine melanoma models.